Opus genetics reports inducement grant under nasdaq listing rule 5635(c)(4)

Research triangle park, n.c., march 19, 2025 (globe newswire) -- opus genetics, inc. (nasdaq: ird), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (irds) and other ophthalmic disorders (“opus” or the “company”), today announced that the independent members of its board of directors approved equity awards under the company's 2021 inducement plan, as amended, as a material inducement to two new employees in connection with the commencement of their employment with the company effective march 13, 2025. the equity awards were approved in accordance with nasdaq listing rule 635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
NDAQ Ratings Summary
NDAQ Quant Ranking